Cargando…

Correction: Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423479/ https://www.ncbi.nlm.nih.gov/pubmed/37402489 http://dx.doi.org/10.1136/ard-2022-223595corr1

Ejemplares similares

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Correction to: Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Correction to: Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort
por: Ometto, Francesca, et al.
Publicado: (2021)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Correction: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Publicado: (2018)

Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Publicado: (2020)

Correction to: Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis
por: Gossec, Laure, et al.
Publicado: (2018)

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
por: Gordon, Kenneth B., et al.
Publicado: (2022)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2021)

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
por: Glatt, Sophie, et al.
Publicado: (2021)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin, Josefina, et al.
Publicado: (2018)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Correction: Fat Metaplasia on Sacroiliac Joint Magnetic Resonance Imaging at Baseline Is Associated with Spinal Radiographic Progression in Patients with Axial Spondyloarthritis
por: Kang, Kwi Young, et al.
Publicado: (2016)

Review of bimekizumab in the treatment of psoriasis
por: Koppu, Sindhuja, et al.
Publicado: (2022)

Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Publicado: (2018)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
por: Coates, Laura C., et al.
Publicado: (2022)

Obesity Increases Disease Activity of Norwegian Patients with Axial Spondyloarthritis: Results from the European Map of Axial Spondyloarthritis Survey
por: Bindesbøll, Christian, et al.
Publicado: (2020)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Inflammatory bowel disease induced by bimekizumab
por: Wietrzykowska-Grishanovich, Dominika, et al.
Publicado: (2022)

Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
por: Ji, Linong, et al.
Publicado: (2021)

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Cytokine profiles in axial spondyloarthritis
por: Madej, Marta, et al.
Publicado: (2015)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Axial Spondyloarthritis and Cigarette Smoking
por: Kaut, Irène Kona, et al.
Publicado: (2017)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Genetics and the axial spondyloarthritis spectrum
por: Brown, Matthew A, et al.
Publicado: (2020)

Work Disability in Axial Spondyloarthritis
por: Nikiphorou, Elena, et al.
Publicado: (2020)

The prevalence of fibromyalgia in axial spondyloarthritis
por: Jones, Gareth T., et al.
Publicado: (2020)

Uncovering the Underworld of Axial Spondyloarthritis
por: Del Vescovo, Sergio, et al.
Publicado: (2023)

Publisher Correction: Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis
por: Hušáková, Markéta, et al.
Publicado: (2020)

Correction to: Efficacy of Mentalization-based group therapy for adolescents: the results of a pilot randomised controlled trial
por: Griffiths, Helen, et al.
Publicado: (2021)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_599e6blnstmioo3863c828vs8a